Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 16/20 | 0.56 |
| ▸ | PDE4A | P27815 | 12/20 | 0.56 |
| ▸ | PDE4C | Q08493 | 11/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 11/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28450908 | 0.86 | PDE4B (0.52) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL29623507 | 0.86 | PDE4B (0.52) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL20363445 | 0.79 | PDE4B (0.58) | PDE4BPDE4APDE4CPDE4DPOLB | |
| SCHEMBL6417347 | 0.76 | POLB (0.57) | PDE4BPDE4APDE4CPDE4DPOLB | |
| SCHEMBL2986800 | 0.76 | PDE4B (0.46) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL7808590 | 0.75 | PDE4B (0.55) | PDE4BPDE4APDE4CPDE4DPOLB | |
| SCHEMBL2987999 | 0.74 | PDE4B (0.48) | PDE4BPDE4APDE4CPDE4DPOLB | |
| SCHEMBL5823060 | 0.74 | PDE4A (0.77) | PDE4BPDE4APDE4CPDE4DPOLB | |
| SCHEMBL7440108 | 0.73 | PDE4B (1.00) | PDE4BPDE4APDE4CPDE4DPOLB | |
| SCHEMBL448221 | 0.73 | PDE4A (0.69) | PDE4BPDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150119399-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2015-04-30 | — | — | US | disclosed |
| US-8163905-B2 | Compounds and their uses 708 | ASTRAZENECA AB (SE) | 2012-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119399-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | IAPP, GPR119, PCNA | PDE4B 1204/4885PDE4A 1173/4885PDE4C 1042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.